STX3

Across TCGA pan-cancer cohorts, STX3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STX3 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher STX3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated STX3 expression acts as an unfavorable survival marker, although some lineages such as OV and HNSC show a favorable association.

OV, LUAD, and PDAC are the cancer types where STX3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Tertile	All	0.819	0.516	.044	8	view →
LUAD	OS	Tertile	III,IV	0.372	0.879	.016	8	view →
PDAC	OS	Median	All	0.455	0.675	.012	4	view →
GBM	DFS	Tertile	All	0.664	0.799	.026	3	view →
HNSC	DFS	Tertile	II,III,IV	0.762	0.538	.047	2	view →
LSCC	OS	Tertile	All	1.000	0.907	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STX3–OV (DFS)

Open the OV breakdown →